Alembic Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: APLLTD BSE: 533573

₹825.45

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #36 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Alembic Pharmaceuticals Limited (this stock)	16,225	22.1	11.8%	-8.7%	1.45%	74	57	82

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹17,352 Cr

EV / EBITDA

14.6x

EV / Sales

2.47x

Market cap / Sales

2.31x

Earnings yield

4.52%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 1,882 Cr, up 25.3% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 197 Cr, up 90.3% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	1,868	256	197	₹10.0200
March 31, 2026	1,719	173	243	₹12.3700
Dec. 31, 2025	1,642	139	114	₹5.8200
Sept. 30, 2025	1,796	216	179	₹9.1200
June 30, 2025	1,494	126	104	₹5.2700
March 31, 2025	1,571	92	75	₹
Dec. 31, 2024	1,406	104	86	₹4.3650
Sept. 30, 2024	1,580	200	166	₹8.4340
June 30, 2024	1,476	213	176	₹8.9640
March 31, 2024	1,475	216	202	₹10.2700
Dec. 31, 2023	1,588	257	233	₹11.8660
Sept. 30, 2023	1,479	134	134	₹6.8090
June 30, 2023	1,332	98	98	₹4.9620

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Total income (before exceptional items)	1,882	1,745	1,653	1,808	1,502	1,422	1,596	1,479	1,482	1,592	1,488	1,344	1,309
Operating revenue	1,868	1,719	1,642	1,796	1,494	1,406	1,580	1,476	1,475	1,588	1,479	1,332	1,307
Other income	14	26	11	11	8	15	16	3	7	3	9	12	2
Operating expenses	1,522	1,445	1,371	1,493	1,280	1,226	1,321	1,184	1,186	1,251	1,271	1,167	1,138
Operating profit	346	274	272	303	214	180	259	291	288	337	207	166	169
Operating profit margin	18.5%	15.9%	16.5%	16.9%	14.3%	12.8%	16.4%	19.8%	19.5%	21.2%	14.0%	12.4%	12.9%
Depreciation	83	82	80	76	73	70	70	69	69	69	67	66	74
Interest	21	19	22	23	23	22	18	13	10	15	15	14	14
Exceptional items, gain / (loss)	—	-25	-42	—	—	—	13	—	—	—	—	—	—
Profit before tax	256	173	139	216	126	104	200	213	216	257	134	98	84
Tax	59	-70	24	37	22	18	34	37	14	23	—	—	-47
Net profit	197	—	114	179	104	86	166	176	202	233	134	98	131
EPS	10.02	12.37	5.82	9.12	5.27	4.37	8.43	8.96	10.27	11.87	6.81	4.96	6.64
Net profit (TTM)	—	—	483	534	531	630	777	745	666	595	481	494	469
EPS (TTM)	37.33	32.58	24.58	27.19	27.03	32.03	39.53	37.91	33.91	30.28	24.47	25.11	23.84

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	6,651	654	640
March 31, 2025	6,033	609	503
March 31, 2024	5,874	704	666
March 31, 2023	5,149	346	347

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	9.2%	5.8%	6,707^†	—	5,905^†	5,153^†	5,061^†	4,267^†	3,667^†	2,954^†	2,979^†
Operating revenue	8.9%	5.7%	6,651	6,033	5,874	5,149	5,051^†	4,133^†	3,660^†	2,945^†	2,977^†
Other income	—	—	56^†	—	31^†	4^†	10^†	135^†	6^†	8^†	2^†
Operating expenses	—	—	5,589^†	—	4,876^†	4,367^†	3,479^†	2,930^†	2,782^†	2,314^†	2,343^†
Operating profit	10.8%	-7.5%	1,063^†	—	999^†	782^†	1,572^†	1,203^†	879^†	631^†	635^†
Operating profit margin	—	—	16.0%^†	—	17.0%^†	15.2%^†	31.1%^†	29.1%^†	24.0%^†	21.4%^†	21.3%^†
Depreciation	—	—	311^†	—	271^†	252^†	153^†	136^†	106^†	102^†	83^†
Interest	—	—	87^†	—	54^†	49^†	13^†	25^†	15^†	2^†	3^†
Exceptional items, gain / (loss)	—	—	-67^†	—	0^†	0^†	0^†	-10^†	0^†	0^†	0^†
Profit before tax	23.7%	-14.3%	654	609	704	346	1,417^†	1,167^†	765^†	535^†	550^†
Tax	—	—	14^†	—	—	—	241^†	197^†	153^†	113^†	119^†
Net profit	22.7%	-11.4%	640	503	666	347	1,175^†	969^†	611^†	422^†	431^†
EPS	11.0%	-11.7%	32.58^†	—	33.91^†	23.84^†	60.79^†	51.42^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	16.0%^†	—	17.0%^†	15.2%^†	31.1%^†	29.1%^†	24.0%^†	21.4%^†	21.3%^†
EBIT margin	11.1%^†	—	12.9%^†	7.7%^†	28.3%^†	28.8%^†	21.3%^†	18.2%^†	18.6%^†
PBT margin	9.8%	10.1%	12.0%	6.7%	28.0%^†	28.2%^†	20.9%^†	18.2%^†	18.5%^†
Net margin	9.6%	8.3%	11.3%	6.7%	23.3%^†	23.5%^†	16.7%^†	14.3%^†	14.5%^†
Interest coverage	8.56x^†	—	13.93x^†	8.07x^†	111.97x^†	47.31x^†	52.39x^†	241.01x^†	215.74x^†
Dividend payout	33.8%^†	—	23.6%^†	42.0%^†	0.0%^†	24.3%^†	—	—	—
Earnings retention	66.2%^†	—	76.4%^†	58.0%^†	100.0%^†	75.7%^†	—	—	—
Current ratio	1.70x	1.71x	—	—	—	—	—	—	—
Quick ratio	0.83x	0.81x	—	—	—	—	—	—	—
Debt to equity	0.20x	0.22x	—	—	—	—	—	—	—
Return on equity	11.4%	9.7%	—	—	—	—	—	—	—
Return on assets	7.9%	6.7%	—	—	—	—	—	—	—
Return on capital employed	12.8%^†	—	—	—	—	—	—	—	—
Asset turnover	0.82x	0.80x	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	809	-483	-318	432	377
March 31, 2025	227	-636	404	563	-336
March 31, 2024	773	-329	-445	325	448
March 31, 2023	730	-461	-261	443	287
March 31, 2022	621	-447	-216	408	213

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	8,151	5,615	5,576	1,149	0	4,001	2,356	23	2,828	2,048
March 31, 2025	7,556	5,195	5,155	1,142	0	3,766	2,200	14	2,513	1,976
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.